The effect of calcium dobesilate on vascular endothelial function, blood pressure, and markers of oxidation in obese male smokers: A placebo-controlled randomised clinical trial

Atherosclerosis

Volumn 170, Issue 1, 2003, Pages 59-72

  Schram, Miranda T ^a   Stam, Frank ^a   De Jongh, Renate T ^a   De Vries, Greetje ^a   Van Dijk, Rob A J M ^a   Serné, Erik H ^a   Lampe, Deva ^a   Nanayakkara, Prabath W B ^a   Tushuizen, Maarten E ^a   Scheffer, Peter G ^a   Schalkwijk, Casper G ^a   Kamper, Ad M ^b   Stehouwer, Coen D A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Blood pressure; Calcium dobesilate; Flow mediated vasodilation; Forearm blood flow; Ketocholesterol; Microcirculation; Nitric oxide; Oxidised LDL

Indexed keywords

ACETYLCHOLINE; DOBESILATE CALCIUM; N(G) METHYLARGININE; NITROPRUSSIDE SODIUM;

ADULT; ARTICLE; BLOOD PRESSURE; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; MALE; MICROCIRCULATION; NORMAL HUMAN; OBESITY; OXIDATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESISTANCE BLOOD VESSEL; SKIN BLOOD FLOW; SMOKING; VASODILATATION;

EID: 10744221226     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00231-4     Document Type: Article

References (50)

1. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97:1996;2601-2610.
2. Celermajer D.S., Adams M.R., Clarkson P., et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. New Engl. J. Med. 334:1996;150-154.
3. Mol M.J., de Rijke Y.B., Demacker P.N., Stalenhoef A.F. Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment. Atherosclerosis. 129:1997;169-176.
4. Yokode M., Kita T., Arai H., Kawai C., Narumiya S., Fujiwara M. Cholesteryl ester accumulation in macrophages incubated with low density lipoprotein pretreated with cigarette smoke extract. Proc. Natl. Acad. Sci. USA. 85:1988;2344-2348.
5. Yokode M., Nagano Y., Arai H., Ueyama K., Ueda Y., Kita T. Cigarette smoke and lipoprotein modification. A possible interpretation for development of atherosclerosis. Ann. New York Acad. Sci. 748:1995;294-300.
6. Harats D., Ben Naim M., Dabach Y., Hollander G., Stein O., Stein Y. Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis. 79:1989;245-252.
7. Cigarette smoking in 99 metropolitan areas - United States, 2000 Morb Mortal Wkly Rep. 2001;50:1107-13.
8. Benarroch I.S., Brodsky M., Rubinstein A., Viggiano C., Salama E.A. Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res. 17:1985;131-138.
9. Beyer J., Meissner K.O., Happ J., Cordes U. Wirkung von calciumdobesilat auf die Permeation von Plasmaprotein beim Diabetiker. Dtsch. Med. Wochenschr. 105:1980;1604-1608.
10. Ruiz E., Lorente R., Tejerina T. Effects of calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated aorta. Br. J. Pharmacol. 121:1997;711-716.
11. Suschek C., Kolb H., Kolb-Bachofen V. Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells. Br. J. Pharmacol. 122:1997;1502-1508.
12. Brunet J., Farine J.C., Garay R.P., Hannaert P. Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat. Eur. J. Pharmacol. 358:1998;213-220.
13. Serne E.H., Stehouwer C.D., ter Maaten J.C., et al. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation. 99:1999;896-902.
14. Brunet J., Farine J.C., Garay R.P., Hannaert P. In vitro antioxidant properties of calcium dobesilate. Fundam. Clin. Pharmacol. 12:1998;205-212.
15. Brown A.J., Jessup W. Oxysterols and atherosclerosis. Atherosclerosis. 142:1999;1-28.
16. Upston J.M., Terentis A.C., Stocker R. Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. FASEB J. 13:1999;977-994.
17. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
18. Serne E.H., Stehouwer C.D., ter Maaten J.C., ter Wee P.M., Donker A.J., Gans R.O. Birth weight relates to blood pressure and microvascular function in normal subjects. J. Hypertens. 18:2000;1421-1427.
19. Serne E.H., Ijzerman R.G., Gans R.O., et al. Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia. Diabetes. 51:2002;1515-1522.
20. Kamper A.M., Paul L.C., Blauw G.J. Prostaglandins are involved in acetylcholine and 5-hydroxytryptamine-induced, nitric oxide-mediated vasodilatation in the human forearm. J. Cardiovasc. Pharmacol. 40:2002;922-929.
21. Blauw G.J., van Brummelen P., Chang P.C., Vermeij P., van Zwieten P.A. 5HT3 receptor-mediated vasodilation in the human forearm. J. Hypertens. Suppl. 6:1988;S33-S35.
22. Bruning T.A., Chang P.C., Blauw G.J., Vermeij P., van Zwieten P.A. Serotonin-induced vasodilatation in the human forearm is mediated by the "nitric oxide-pathway": no evidence for involvement of the 5-HT3-receptor. J. Cardiovasc. Pharmacol. 22:1993;44-51.
23. Bruning T.A., Chang P.C., Kemme M.J., Vermeij P., Pfaffendorf M., van Zwieten P.A. Comparison of cholinergic vasodilator responses to acetylcholine and methacholine in the human forearm. Blood Press. 5:1996;333-341.
24. Kamper A.M., de Craen A.J., Blauw G.J. Forearm blood flow measurements using computerized R-wave triggered strain-gauge venous occlusion plethysmography: unilateral vs. bilateral measurements. Clin. Physiol. 21:2001;524-527.
25. Calver A., Collier J., Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J. Clin. Invest. 90:1992;2548-2554.
26. Stroes E.S., Koomans H.A., de Bruin T.W., Rabelink T.J. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 346:1995;467-471.
27. Stroes E.S., Joles J.A., Chang P.C., Koomans H.A., Rabelink T.J. Impaired endothelial function in patients with nephrotic range proteinuria. Kidney Int. 48:1995;544-550.
28. Lambert J., Aarsen M., Donker A.J., Stehouwer C.D. Endothelium-dependent and -independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 16:1996;705-711.
29. Lambert J., van den B.M., Steyn M., Rauwerda J.A., Donker A.J., Stehouwer C.D. Familial hyperhomocysteinaemia and endothelium-dependent vasodilatation and arterial distensibility of large arteries. Cardiovasc. Res. 42:1999;743-751.
30. Sandhoff R., Brugger B., Jeckel D., Lehmann W.D., Wieland F.T. Determination of cholesterol at the low picomole level by nano- electrospray ionization tandem mass spectrometry. J. Lipid Res. 40:1999;126-132.
31. Holvoet P., Vanhaecke J., Janssens S., Van de W.F., Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 98:1998;1487-1494.
32. Serne E.H., Gans R.O., ter Maaten J.C., ter Wee P.M., Donker A.J., Stehouwer C.D. Capillary recruitment is impaired in essential hypertension and relates to insulin's metabolic and vascular actions. Cardiovasc. Res. 49:2001;161-168.
33. Vervoort G., Wetzels J.F., Lutterman J.A., van Doorn L.G., Berden J.H., Smits P. Elevated skeletal muscle blood flow in noncomplicated type 1 diabetes mellitus: role of nitric oxide and sympathetic tone. Hypertension. 34:1999;1080-1085.
34. van Guldener C., Lambert J., Janssen M.J., Donker A.J., Stehouwer C.D. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol. Dial Trans. 12:(Suppl. 2):1997;14-18.
35. Lamon-Fava S., Wilson P.W., Schaefer E.J. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 16:1996;1509-1515.
36. Ruiz E., Tejerina T. Calcium dobesilate increases endothelium-dependent relaxation in endothelium-injured rabbit aorta. Pharmacol. Res. 38:1998;361-366.
37. Tejerina T., Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen. Pharmacol. 31:1998;357-360.
38. Ruiz E., Tejerina T. Calcium dobesilate increased endothelium-dependent relaxation in isolated rabbit aorta. Gen. Pharmacol. 30:1998;713-718.
39. Sanz M., Ruiz E., Ganado P., Tejerina T. In vitro effects of calcium dobesilate on the responsiveness of spontaneously diabetic rat aorta. Jpn. J. Pharmacol. 78:1998;391-394.
40. Carr A.C., Zhu B.Z., Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ. Res. 87:2000;349-354.
41. Sevin R., Cuendet J.F. The action of calcium dobesilate on capillary permeability in diabetics. Ophthalmologica. 162:1971;33-40.
42. Grignolo F.M., Musso M., Borromeo P., Sebastiani F. Fluorescence iris angiography in the assessment of calcium dobesilate therapy in the treatment of diabetic microangiopathy. Ophthalmologica. 178:1979;250-258.
43. Adank C., Koerner F. Calcium dobesilate in diabetic retinopathy. A retrospective controlled study. Ophthalmologica. 190:1985;102-111.
44. Benarroch I.S., Brodsky M., Rubinstein A., Viggiano C., Salama E.A. Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res. 17:1985;131-138.
45. Tamas P., Csermely T., Ertl T., Vizer M., Szabo I., Prievara F.T. Calcium dobesilate lowers the blood pressure in mild to moderate midtrimester hypertension: a pilot study. Gynecol. Obstet. Invest. 47:1999;210-213.
46. Widmer L., Biland L., Barras J.P. Doxium 500 in chronic venous insufficiency: a double-blind placebo controlled multicentre study. Int. Angiol. 9:1990;105-110.
47. John S., Schlaich M., Langenfeld M., et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation. 98:1998;211-216.
48. Casino P.R., Kilcoyne C.M., Quyyumi A.A., Hoeg J.M., Panza J.A. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation. 88:1993;2541-2547.
49. Panza J.A., Casino P.R., Kilcoyne C.M., Quyyumi A.A. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 87:1993;1468-1474.
50. Calver A., Collier J., Moncada S., Vallance P. Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J. Hypertens. 10:1992;1025-1031.